Though venture capital gets most of the spotlight when it comes to fundraising, life sciences entrepreneurs and researchers should not underestimate the opportunities in non-dilutive capital for their startups. There are a number of financing and government agencies with programs and funds set aside to help bioscience innovations find their footing. Learn more about how to identify the right ones, insights into how to increase your chances for success and challenges anticipated in the wake of the COVID crisis. This is the final session in our four-part BioEDU Business of Bioscience series, which take place every Thursday at 9:00 a.m. and feature live conversations with bioscience industry veterans. Particular emphasis will be given to concerns relevant to healthcare startups in a post-COVID environment.
- Tyler Allchin, BioEnterprise Director of Talent and Expansion
- Liz Powell, G2G Founder and President
- Greg Kapcar, G2G Public Affairs Director
- Michael Bruckman, Haima Therapeutics COO and Interim CEO